Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Hereditary Angioedema due to C1-Inhibitor Deficiency in Pediatric Patients in Croatia – First National Study, Diagnostic and Prophylactic Challenges (CROSBI ID 277505)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Karadža-Lapić, Lj ; Barešić, M ; Vrsalović, R ; Ivković-Jureković ; I ; Sršen, S ; Prkačin, I ; Rijavec, M ; Cikojević, Draško Hereditary Angioedema due to C1-Inhibitor Deficiency in Pediatric Patients in Croatia – First National Study, Diagnostic and Prophylactic Challenges // Acta clinica Croatica, 58 (2019), 139-146. doi: 10.20471/acc.2019.58.01.18

Podaci o odgovornosti

Karadža-Lapić, Lj ; Barešić, M ; Vrsalović, R ; Ivković-Jureković ; I ; Sršen, S ; Prkačin, I ; Rijavec, M ; Cikojević, Draško

engleski

Hereditary Angioedema due to C1-Inhibitor Deficiency in Pediatric Patients in Croatia – First National Study, Diagnostic and Prophylactic Challenges

Hereditary angioedema (HAE) is a rare autosomal dominant disease with deficiency (type I) or dysfunction (type II) of C1 inhibitor, caused by mutations in the C1-INH gene, characterized by recurrent submucosal or subcutaneous edemas including skin swelling, abdominal pain and life- threatening episodes of upper airway obstruction. The aim of this study was to investigate healthcare experiences in children with HAE due to C1 inhibitor deficiency (C1- INH-HAE) in Croatia in order to estimate the number of affected children and to recommend management protocols for diagnosis, short-term prophylaxis and acute treatment. Patients were recruited during a 4-year period at five hospitals in Croatia. Complement testing was performed in patients with a positive family history. This pilot study revealed nine pediatric patients positive for C1-INH- HAE type I, aged 1-16 years, four of them asymptomatic. Before the age of one year, C1- INH levels may be lower than in adults ; it is advisable to confirm C1-INH-HAE after the age of one year. Plasma-derived C1-INH is recommended as acute and short-term prophylactic treatment. Recombinant C1-INH and icatibant are licensed for the acute treatment of pediatric patients. In Croatia, HAE is still underdiagnosed in pediatric population.

Hereditary angioedema types I and II-diagnosis ; complement C1 inhibitor protein ; child ; Croatia

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

58

2019.

139-146

objavljeno

0353-9466

1333-9451

10.20471/acc.2019.58.01.18

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost